CD274 and cancer: More encouragingly, ELISE could be extended to accurately estimate the responsiveness of various immunotherapeutic agents against other cancers, including PD1/PD-L1 suppressor against metastatic urothelial cancer (AUC = 88.86%), and MAGE−A3 immunotherapy against metastatic melanoma (AUC = 100.00%).